Association of KMT2C Genetic Variants with the Clinicopathologic Development of Oral Cancer

被引:9
|
作者
Shieu, Mu-Kuei [1 ]
Ho, Hsin-Yu [2 ]
Lin, Shu-Hui [3 ,4 ]
Lo, Yu-Sheng [2 ]
Lin, Chia-Chieh [2 ]
Chuang, Yi-Ching [2 ]
Hsieh, Ming-Ju [2 ,5 ,6 ]
Chen, Mu-Kuan [7 ]
机构
[1] Changhua Christian Hosp, Dept Med Educ, Div Gen Practice, Changhua 500, Taiwan
[2] Changhua Christian Hosp, Oral Canc Res Ctr, Changhua 500, Taiwan
[3] Changhua Christian Hosp, Dept Surg Pathol, Changhua 500, Taiwan
[4] Cent Taiwan Univ Sci & Technol, Dept Med Lab Sci & Biotechnol, Taichung 406, Taiwan
[5] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung 402, Taiwan
[6] China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan
[7] Changhua Christian Hosp, Dept Otorhinolaryngol Head & Neck Surg, Changhua 500, Taiwan
关键词
oral squamous cell carcinoma; lysine methyltransferase 2C; single-nucleotide polymorphisms; alcohol drinking; SINGLE NUCLEOTIDE POLYMORPHISMS; RISK; ALCOHOL; CAVITY;
D O I
10.3390/ijerph19073974
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Lysine methyltransferase 2C (KMT2C) is a tumor-suppressor gene in several myeloid cells and epithelia and is linked with blood and solid tumor cancers. KMT2C single-nucleotide polymorphisms (SNPs) are also connected with several cancer types. Our study aimed to explore the potential genetic polymorphisms of KMT2C in oral cancer. Five KMT2C SNPs, including rs201834857, rs4725443, rs6464221, rs74483926, and rs6943984, were evaluated in 284 cancer-free controls and 284 oral squamous cell carcinoma (OSCC) cases. We found that individuals with the TC genotype or TC + CC genotype of rs4725443 had a higher risk of oral cancer incidence than those with the TT genotype. Further analysis of KMT2C SNP rs4725443 revealed that the TC + CC genotype of rs4725443 was associated with a significantly advanced tumor stage in the non-alcohol-drinking population. Moreover, the TC + CC genotype of rs4725443 was connected with poor cell differentiation in the alcohol-drinking population. Through analyzing a dataset from The Cancer Genome Atlas (TCGA), we found that reduced KMT2C levels were associated with advanced tumor stage, lymph node invasion, and poor cell differentiation in head and neck squamous cell carcinomas. Our data suggest that KMT2C SNP rs4725443 is a potential genetic marker for oral cancer patients in both non-alcohol-drinking and alcohol-drinking populations.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer
    Simigdala, Nikiana
    Chalari, Anna
    Sklirou, Aimilia D.
    Chavdoula, Evangelia
    Papafotiou, George
    Melissa, Pelagia
    Kafalidou, Aimilia
    Paschalidis, Nikolaos
    Pateras, Ioannis S.
    Athanasiadis, Emmanouil
    Konstantopoulos, Dimitris
    Trougakos, Ioannis P.
    Klinakis, Apostolos
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2023, 80 (04)
  • [42] Association of KMT2C mutations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.
    Liu, Chunling
    Duan, Qianqian
    Zhang, Qin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis
    Limberger, Tanja
    Schlederer, Michaela
    Trachtova, Karolina
    Alonso, Ines Garces de los Fayos
    Yang, Jiaye
    Hoegler, Sandra
    Sternberg, Christina
    Bystry, Vojtech
    Oppelt, Jan
    Tichy, Boris
    Schmeidl, Margit
    Kodajova, Petra
    Jaeger, Anton
    Neubauer, Heidi A.
    Oberhuber, Monika
    Schmalzbauer, Belinda S.
    Pospisilova, Sarka
    Dolznig, Helmut
    Wadsak, Wolfgang
    Culig, Zoran
    Turner, Suzanne D.
    Egger, Gerda
    Lagger, Sabine
    Kenner, Lukas
    MOLECULAR CANCER, 2022, 21 (01)
  • [44] COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer
    Fagan, Richard J.
    Dingwall, Andrew K.
    CANCER LETTERS, 2019, 458 : 56 - 65
  • [45] Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer
    Nikiana Simigdala
    Anna Chalari
    Aimilia D. Sklirou
    Evangelia Chavdoula
    George Papafotiou
    Pelagia Melissa
    Aimilia Kafalidou
    Nikolaos Paschalidis
    Ioannis S. Pateras
    Emmanouil Athanasiadis
    Dimitris Konstantopoulos
    Ioannis P. Trougakos
    Apostolos Klinakis
    Cellular and Molecular Life Sciences, 2023, 80
  • [46] Significance of KMT2C and TSC2 in the Development of Acquired Cystic Disease-associated Renal Cell Carcinoma
    Kojima, Fumiyoshi
    Matsuzaki, Ibu
    Hara, Isao
    Murata, Shin-ichi
    LABORATORY INVESTIGATION, 2024, 104 (03) : S975 - S976
  • [47] Correlation of TP53/KMT2C co-mutation and Tumor Microenvironment in Lung Cancer
    Zhang, X.
    Zhang, L.
    Ren, B.
    Tang, X.
    Liu, H.
    Wang, Y.
    Zhang, Z.
    Zhao, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1143 - S1144
  • [48] KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis
    Tanja Limberger
    Michaela Schlederer
    Karolina Trachtová
    Ines Garces de los Fayos Alonso
    Jiaye Yang
    Sandra Högler
    Christina Sternberg
    Vojtech Bystry
    Jan Oppelt
    Boris Tichý
    Margit Schmeidl
    Petra Kodajova
    Anton Jäger
    Heidi A. Neubauer
    Monika Oberhuber
    Belinda S. Schmalzbauer
    Sarka Pospisilova
    Helmut Dolznig
    Wolfgang Wadsak
    Zoran Culig
    Suzanne D. Turner
    Gerda Egger
    Sabine Lagger
    Lukas Kenner
    Molecular Cancer, 21
  • [49] Genetic variants of dipeptidyl peptidase IV are linked to the clinicopathologic development of prostate cancer
    Wen, Yu-Ching
    Lin, Chia-Yen
    Hsiao, Chi-Hao
    Wang, Shian-Shiang
    Huang, Hsiang-Ching
    Lin, Yung-Wei
    Ho, Kuo-Hao
    Chang, Lun-Ching
    Yang, Shun-Fa
    Chien, Ming-Hsien
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2023, 27 (17) : 2507 - 2516
  • [50] Identification of a Rare Novel KMT2C Mutation That Presents with Schizophrenia in a Multiplex Family
    Chen, Chia-Hsiang
    Huang, Ailing
    Huang, Yu-Shu
    Fang, Ting-Hsuan
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (12):